Mortality from acute myocarditis between 2007 to 2022: Insights from a US nationwide registry

Q: What is the clinical evidence from this study?

Study design: Letter. Population: Acute myocarditis. Intervention: Year 2022 vs. Year 2007. Primary outcome: Age-adjusted mortality rate for all types of acute myocarditis (per 100,000) (71% reduction).

Q: What does this research mean for the field?

Age-adjusted mortality from acute myocarditis in the United States decreased by 71% between 2007 and 2022, despite transient mortality surges during major viral outbreaks including the 2020 COVID-19 pandemic. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Camilla Mattiuzzi; Giuseppe Lippi; Giuseppe Lippi

doi:10.23750/abm.v96i2.16656

April 24, 2025Acta bio-medica dell'Ateneo parmense/Acta biomedicaOpen Access

Mortality from acute myocarditis between 2007 to 2022: Insights from a US nationwide registry

View Full Paper

Ask AI

Bookmark

Share

Key result

US acute myocarditis mortality drops ~71% between 2007 and 2022.

71% reduction

Why the study?

Mortality trends for acute myocarditis in the US between 2007 and 2022 were unclear, especially regarding the impact of COVID-19 and other infectious causes.

Key Points

To assess long-term trends in age-adjusted mortality from acute myocarditis and acute infective myocarditis in the United States between 2007 and 2022.
Extracted death records from the CDC WONDER nationwide epidemiologic repository covering US residents from 2007 through 2022.
Identified cases using ICD-10 codes I40 for all types of acute myocarditis and I40.0 for acute infective myocarditis.
Calculated age-adjusted death rates per 100,000 population alongside 95% confidence intervals.
The age-adjusted death rate for all acute myocarditis fell 71% from 0.097×100,000 in 2007 to 0.028×100,000 in 2022.
The death rate for acute infective myocarditis decreased by 90% from 0.067×100,000 in 2007 to 0.007×100,000 in 2022.
Acute infective myocarditis exhibited mortality peaks in 2013, 2016, and 2020, with 2020 rates more than three times higher than 2019 (0.046 vs. 0.014×100,000).

Structured PICO

P

Population

US nationwide population data from the CDC WONDER database assessing age-adjusted mortality rates for acute myocarditis between 2007 and 2022.

O

Outcome

Age-adjusted death rate (per 100,000) for acute myocarditis and acute infective myocarditishard clinical

Main Result

Effect estimate: 71% reduction

Absolute Event Rate: 0.028% vs 0.097%

Limitations

Reliance on ICD-10 coding from a nationwide death registry, which may be subject to misclassification or changes in diagnostic practices
Differences in population characteristics and mortality data collection approaches limit direct comparisons with other countries

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Mortality from acute myocarditis in the US decreased significantly from 2007 to 2022, despite a transient spike in 2020 likely related to the COVID-19 pandemic.

Abstract

N/A for Letters to the Editor

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mattiuzzi et al. (2025) conducted a letter in Acute myocarditis. Year 2022 vs. Year 2007 was evaluated on Age-adjusted mortality rate for all types of acute myocarditis (per 100,000) (71% reduction). The age-adjusted mortality rate for all types of acute myocarditis in the US decreased by 71% between 2007 and 2022, dropping from 0.097 to 0.028 per 100,000.

synapsesocial.com/papers/6ac19d70aeea5716e8c6c681 https://doi.org/10.23750/abm.v96i2.16656

View Full Paper

Ask AI

Bookmark

Share

Mortality from acute myocarditis between 2007 to 2022: Insights from a US nationwide registry

Key Points

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Mortality from acute myocarditis between 2007 to 2022: Insights from a US nationwide registry

Key Points

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading